Immuneering (IMRX) Change in Receivables (2020 - 2023)
Immuneering's (IMRX) quarterly Change in Receivables came in at -$1046.0 in Q2 2023, up 98.97% year-on-year from -$525.72 in Q2 2022, and up 90.8% quarter-over-quarter from -$11371.0 in Q1 2023.
Immuneering (IMRX) Change in Receivables (2020 - 2023) Analysis & Trends
Immuneering's Change in Receivables history runs 4 years deep, the most recent figure standing at -$1046.0 for Q2 2023.
- On a quarterly basis, Change in Receivables rose 98.97% year-over-year to -$1046.0 in Q2 2023; TTM through Mar 2024 was -$1046.0, a 99.62% increase from a year earlier, with the FY2023 full-year figure at -$12417.0, up 94.69% from the prior year.
- Change in Receivables rose to -$1046.0 in Q2 2023 per IMRX's latest filing, from -$11371.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $278185.0 in Q3 2020 and bottomed at -$250978.0 in Q4 2021.
- The 4-year median for Change in Receivables is -$17550.5 (2021), against an average of -$27133.6.
- Biggest YoY gain for Change in Receivables was 535.73% in 2022; the steepest drop was 3847.7% in 2022.
- Year by year, Change in Receivables stood at -$78035.0 in 2020, then tumbled by 221.62% to -$250978.0 in 2021, then surged by 76.98% to -$57763.0 in 2022, then soared by 98.19% to -$1046.0 in 2023.
- Per Business Quant, the three latest IMRX Change in Receivables figures stand at -$1046.0 (Q2 2023), -$11371.0 (Q1 2023), and -$57763.0 (Q4 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Immuneering | 279.33 Mn | 279.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -1,046.00 |
| Jun 30, 2023 | -1,046.00 |
| Mar 31, 2023 | -11,371.00 |
| Mar 31, 2023 | -11,371.00 |
| Dec 31, 2022 | -57,763.00 |
| Dec 31, 2022 | -57,763.00 |
| Sep 30, 2022 | -108,245.00 |
| Sep 30, 2022 | -108,245.00 |
| Jun 30, 2022 | -101,188.00 |
| Jun 30, 2022 | -101,188.00 |
| Mar 31, 2022 | 33,573.00 |
| Mar 31, 2022 | 33,573.00 |
| Dec 31, 2021 | -250,978.00 |
| Dec 31, 2021 | -250,978.00 |
| Sep 30, 2021 | -23,730.00 |
| Sep 30, 2021 | -23,730.00 |
| Jun 30, 2021 | 2,700.00 |
| Jun 30, 2021 | 2,700.00 |
| Mar 31, 2021 | -7,705.00 |
| Mar 31, 2021 | -7,705.00 |